BofA/Merrill Lynch Downgrades Quest Diagnostics (DGX) to Underperform
Tweet Send to a Friend
BofA/Merrill Lynch analyst Derik de Bruin downgraded Quest Diagnostics (NYSE: DGX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
